Rising OAIs bring spotlight back on regulatory compliance at Indian pharma companies

Rising OAIs bring spotlight back on regulatory compliance at Indian pharma companies USFDA classifies its inspection as OAI for plants found in an unacceptable state of compliance with regard to current good manufacturing practice (CGMP).

No comments:

Post a Comment